Here’s why Abbott Labs stock is getting dinged after a strong earnings beat

Earnings

Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.
Ethan Miller | Getty Images

Abbott Labs delivered a second-quarter earnings beat on Thursday, but the company’s ongoing litigation over its baby formula — plus softer guidance for the current quarter — is dragging down shares. We view the pullback as an opportunity.

Articles You May Like

3 Top Stocks That Aren’t the Mag 7
Zacks Strategist Shaun Pruitt Discusses The Real Trump Trade
Pandemic Stock Winners Shopify, Peloton and Zoom: Buying Opportunities in 2025?
Tesla Beats Delivery Expectations, Stock Sells Off
Astera Labs (ALAB) and Cracker Barrel Old Country Store (CBRL): 10/6/25 Bull & Bear